MX2023004880A - AGONISTA DE IL-2/IL-15RßY PARA EL TRATAMIENTO DE CÁNCER DE PIEL QUE NO ES MELANOMA. - Google Patents

AGONISTA DE IL-2/IL-15RßY PARA EL TRATAMIENTO DE CÁNCER DE PIEL QUE NO ES MELANOMA.

Info

Publication number
MX2023004880A
MX2023004880A MX2023004880A MX2023004880A MX2023004880A MX 2023004880 A MX2023004880 A MX 2023004880A MX 2023004880 A MX2023004880 A MX 2023004880A MX 2023004880 A MX2023004880 A MX 2023004880A MX 2023004880 A MX2023004880 A MX 2023004880A
Authority
MX
Mexico
Prior art keywords
agonist
skin cancer
melanoma skin
15rbî2ò
treating non
Prior art date
Application number
MX2023004880A
Other languages
English (en)
Inventor
Ulrich Moebius
David Béchard
Irena Adkins
Stefano Ferrara
Nada Podzimkova
Original Assignee
Cytune Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytune Pharma filed Critical Cytune Pharma
Publication of MX2023004880A publication Critical patent/MX2023004880A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un agonista de interleucina-2/receptor ß? de interleucina-15 (IL-2/IL-15Rß?) para usarse en el tratamiento del cáncer de la piel que no es melanoma. También se proporcionan esquemas de dosificación para el tratamiento de los pacientes con cáncer de la piel que no es melanoma con un agonista de IL-2/IL-15Rß?.
MX2023004880A 2020-10-26 2021-10-26 AGONISTA DE IL-2/IL-15RßY PARA EL TRATAMIENTO DE CÁNCER DE PIEL QUE NO ES MELANOMA. MX2023004880A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20203907 2020-10-26
PCT/EP2021/079635 WO2022090202A1 (en) 2020-10-26 2021-10-26 IL-2/IL-15RBβү AGONIST FOR TREATING NON-MELANOMA SKIN CANCER

Publications (1)

Publication Number Publication Date
MX2023004880A true MX2023004880A (es) 2023-05-11

Family

ID=73020106

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004880A MX2023004880A (es) 2020-10-26 2021-10-26 AGONISTA DE IL-2/IL-15RßY PARA EL TRATAMIENTO DE CÁNCER DE PIEL QUE NO ES MELANOMA.

Country Status (9)

Country Link
US (1) US20230398185A1 (es)
EP (1) EP4232068A1 (es)
JP (1) JP2023550880A (es)
KR (1) KR20230096047A (es)
AU (1) AU2021372660A1 (es)
CA (1) CA3195276A1 (es)
IL (1) IL302313A (es)
MX (1) MX2023004880A (es)
WO (1) WO2022090202A1 (es)

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US7371371B2 (en) 2001-08-13 2008-05-13 University Of Southern California Interleukin-2 mutants with reduced toxicity
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
JP5744369B2 (ja) 2004-02-27 2015-07-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ＩＬ１５−Ｒα用ＩＬ−１５結合部位およびアゴニスト／アンタゴニスト活性を有する特異的ＩＬ−１５突然変異体
WO2006017853A2 (en) 2004-08-11 2006-02-16 Beth Israel Deaconess Medical Center, Inc. Mutant interleukin-15-containing compositions and suppression of an immune response
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
AU2007271398B2 (en) 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
CA3028038C (en) 2007-05-11 2021-08-10 Altor Bioscience Corporation Fusion molecules and il-15 variants
WO2009135031A1 (en) 2008-04-30 2009-11-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Substituted il-15
KR20230148396A (ko) 2010-11-12 2023-10-24 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
SI2673294T1 (sl) 2011-02-10 2016-08-31 Roche Glycart Ag Mutirani polipeptidi interlevkina-2
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
AU2013334610B2 (en) 2012-10-24 2018-09-13 Novartis Ag IL-15R alpha forms, cells expressing IL-15R alpha forms, and therapeutic uses of IL-15R alpha and IL-15/IL-15R alpha complexes
KR102561553B1 (ko) 2013-03-15 2023-07-31 젠코어 인코포레이티드 이형이량체 단백질
ES2698375T3 (es) 2013-06-27 2019-02-04 Inst Nat Sante Rech Med Antagonistas de interleucina 15 (IL-15) y usos de los mismos para el tratamiento de enfermedades autoinmunes y enfermedades inflamatorias
HRP20212023T1 (hr) 2013-08-08 2022-04-01 Cytune Pharma Modulokini temeljeni na il-15 i il-15ralpha sushi domeni
WO2015103928A1 (zh) 2014-01-08 2015-07-16 上海恒瑞医药有限公司 Il-15异源二聚体蛋白及其用途
PL3094351T3 (pl) 2014-01-15 2022-06-27 Kadmon Corporation, Llc Środki immunomodulujące
JP2017536098A (ja) 2014-10-14 2017-12-07 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１５組成物及びその使用
AU2015366795B2 (en) 2014-12-19 2020-12-17 Jiangsu Hengrui Medicine Co., Ltd. Interleukin 15 protein complex and use thereof
EP3064507A1 (en) 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
CN112574316A (zh) 2015-07-02 2021-03-30 博际生物医药科技(杭州)有限公司 用于肿瘤靶向治疗的白细胞介素-15融合蛋白
WO2017046200A1 (en) 2015-09-16 2017-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases
US20170088597A1 (en) 2015-09-25 2017-03-30 Altor Bioscience Corporation Interleukin-15 superagonist significantly enhances graft-versus-tumor activity
AU2016369537B2 (en) * 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
BR112018012262A2 (pt) 2015-12-21 2018-12-04 Armo Biosciences Inc composições de interleucina-15 e seus usos
SG11201903302UA (en) 2016-10-14 2019-05-30 Xencor Inc Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
BR112019007920A2 (pt) * 2016-10-21 2019-10-08 Altor Bioscience Corp moléculas multiméricas à base de il-15
MX2019006072A (es) 2016-11-30 2019-08-14 Oncomed Pharm Inc Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit).
AU2018205276A1 (en) * 2017-01-06 2019-07-18 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
US20200237874A1 (en) * 2017-01-20 2020-07-30 Novartis Ag Combination therapy for the treatment of cancer
WO2018151868A2 (en) 2017-02-16 2018-08-23 Sonnet Bio Therapeutics Albumin binding domain fusion proteins
US20200078467A1 (en) 2017-05-15 2020-03-12 Nektar Therapeutics Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
WO2019028425A1 (en) 2017-08-03 2019-02-07 Synthorx, Inc. CONJUGATES OF CYTOKINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
MX2020008772A (es) 2018-02-26 2020-10-01 Synthorx Inc Conjugados de il-15, y sus usos.
SG11202008261WA (en) 2018-03-08 2020-09-29 Rubius Therapeutics Inc Therapeutic cell systems and methods for treating cancer and infectious diseases
WO2020021465A1 (en) * 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
WO2020069398A1 (en) 2018-09-27 2020-04-02 Akrevia Therapeutics Inc. Masked cytokine polypeptides
KR20210118870A (ko) * 2019-01-21 2021-10-01 사노피 진행성 단계의 고형 종양 암에 대한 치료용 rna 및 항-pd1 항체
MX2021013766A (es) 2019-05-14 2022-02-21 Werewolf Therapeutics Inc Restos de separacion y metodos de uso de los mismos.
WO2020234387A1 (en) * 2019-05-20 2020-11-26 Cytune Pharma IL-2/IL-15Rßy AGONIST DOSING REGIMENS FOR TREATING CANCER OR INFECTIOUS DISEASES
US20220370563A1 (en) 2019-10-25 2022-11-24 Neoleukin Therapeutics, Inc. Methods of administration of il-2 receptor agonists
MX2022009611A (es) 2020-02-05 2022-11-07 Novartis Ag Celula cho que expresa heterodimeros il-15.

Also Published As

Publication number Publication date
AU2021372660A1 (en) 2023-06-01
EP4232068A1 (en) 2023-08-30
KR20230096047A (ko) 2023-06-29
JP2023550880A (ja) 2023-12-06
IL302313A (en) 2023-06-01
CA3195276A1 (en) 2022-05-05
US20230398185A1 (en) 2023-12-14
AU2021372660A9 (en) 2024-05-02
WO2022090202A8 (en) 2023-05-11
WO2022090202A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
MX2019011679A (es) Reemplazo de un pre-acondicionamiento citotoxico antes de una inmunoterapia celular.
UA106318C2 (ru) Производный полипептид il-2 с агонистической активностью для лечения рака и хронических инфекций
WO2013045125A8 (en) Immunocytokine combination therapy
PH12019502621A1 (en) Antibody-cytokine engrafted proteins and methods of use in the treatement of cancer
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
MX2021005761A (es) Anticuerpos anti-proteína alfa reguladora de señal (anti-sirpalfa) humanizados.
MX2022013174A (es) Semaglutida para el tratamiento de la esteatohepatitis no alcoholica.
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
MX2018014432A (es) Materiales y metodos relacionados con el diseño del regimen de dosificacion.
MX2020001727A (es) Terapia de combinacion.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2021014189A (es) Regimenes de dosificacion de agonistas de la il-2/il-15r?y para el tratamiento del cancer o enfermedades infecciosas.
ZA202204809B (en) 5-ht2a agonists for use in treatment of depression
MX2022003886A (es) Dominio extracelular modificado del receptor del factor estimulante de colonias de granulocitos (g-csfr) y citocinas que lo unen.
MX2023004880A (es) AGONISTA DE IL-2/IL-15RßY PARA EL TRATAMIENTO DE CÁNCER DE PIEL QUE NO ES MELANOMA.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
NZ713129A (en) Oxprenolol compositions for treating cancer
MX2023004879A (es) AGONISTA DE IL-2/IL-15RßY PARA EL TRATAMIENTO DEL CARCINOMA DE CÉLULAS ESCAMOSAS.
WO2019070161A3 (en) Articles and methods directed to personalized therapy of cancer
MX2022011888A (es) Tratamiento de trastornos respiratorios.
MX2021011799A (es) Antagonistas de semaforina 4d para usarlos en la terapia contra el cancer.
BR112021016923A2 (pt) Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits
MX2022008843A (es) Metodos para tratar cancer con inhibidores de farnesiltransferasa.
ZA201907369B (en) Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment